Gelteq Limited Ordinary Shares (GELS) - Total Assets
Based on the latest financial reports, Gelteq Limited Ordinary Shares (GELS) holds total assets worth $21.48 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GELS net assets for net asset value and shareholders' equity analysis.
Gelteq Limited Ordinary Shares - Total Assets Trend (2020–2025)
This chart illustrates how Gelteq Limited Ordinary Shares's total assets have evolved over time, based on quarterly financial data.
Gelteq Limited Ordinary Shares - Asset Composition Analysis
Current Asset Composition (June 2025)
Gelteq Limited Ordinary Shares's total assets of $21.48 Million consist of 7.0% current assets and 93.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.6% |
| Accounts Receivable | $459.72K | 2.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $19.86 Million | 92.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Gelteq Limited Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see GELS stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gelteq Limited Ordinary Shares's current assets represent 7.0% of total assets in 2025, a decrease from 92.8% in 2020.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2025, down from 51.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 92.0% of total assets, an increase from 7.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 92.5% of total assets.
Gelteq Limited Ordinary Shares Competitors by Total Assets
Key competitors of Gelteq Limited Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Gelteq Limited Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.27 | 0.08 | 1.59 |
| Quick Ratio | 0.27 | 0.08 | 1.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-4.13 Million | $-3.56 Million | $139.01K |
Gelteq Limited Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between Gelteq Limited Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | 3.5% |
| Total Assets | $21.48 Million |
| Market Capitalization | $7.05 Million USD |
Valuation Analysis
Below Book Valuation: The market values Gelteq Limited Ordinary Shares's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Gelteq Limited Ordinary Shares's assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Gelteq Limited Ordinary Shares (2020–2025)
The table below shows the annual total assets of Gelteq Limited Ordinary Shares from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $21.48 Million | +3.46% |
| 2024-06-30 | $20.76 Million | -7.72% |
| 2023-06-30 | $22.49 Million | -3.91% |
| 2022-06-30 | $23.41 Million | -3.34% |
| 2021-06-30 | $24.22 Million | +3811.86% |
| 2020-06-30 | $619.12K | -- |
About Gelteq Limited Ordinary Shares
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.